DOI 10.53511/PHARMKAZ.2023.39.97.013
S.B. Kaydarova, T.B. Kadyssov, N.M. Urazalina, S.O. Rakhyzhanova, G.M. Muftiyeva, A.A. Abenov, Zh.U. Kozykenova
Semey Medical University NСJSC, Semey, Republic of Kazakhstan
HISTOLOGICAL AND MOLECULAR GENETIC CHARACTERISTICS OF CLINICALLY
AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA:
A LITERATURE REVIEW
Resume: Papillary thyroid carcinoma (PTC) is the most common thyroid cancer; this cancer presents relatively low malignancy, good prognosis, and a 10-year survival rate of over 90 %. However, the clinical behaviors of this cancer are complex and varied. PTC is easy to spread via lymphatic ducts, which results in recurrence, metastases, and even death [1]. Differentiated thyroid cancer has a favorable prognosis in terms of relapsefree and overall survival. However, some cases of differentiated thyroid cancer (TC) are characterized by aggressive course with distant metastases. Identification of histological subtypes of papillary thyroid cancer (PTC) and detection of specific mutations may have some prognostic value in the prediction of the disease course and clinical response to treatment. The severity of the disease depends on multiple clinical characteristics, morphological and molecular features of the tumor. Several histological variants of PTC with varying degrees of malignancy have been described so far: from well-differentiated PTC to radioiodine refractory undifferentiated anaplastic carcinoma with a high mitotic index and high probability of relapses. Recurrent PTC mainly refers to localized and distant recurrence, including recurrence of the primary tumor, lymph node metastases, invasion of the esophagus and trachea, invasion of muscles, soft tissues and nerves, and distant metastases. Many factors can affect the recurrence of thyroid cancer, and final conclusion has not yet been reached. Aim: to summarize the available literature data on the molecular genetic characteristics of aggressive variants of papillary thyroid carcinoma. Methods: We conducted a literature review of scientific papers over the past decade using PubMed search engine resources. In addition, a search was conducted using the data of the scientific electronic library eLIBRARY for the above keywords. For this meta-analysis, we used articles containing clinical evidence on the most recent issues regarding aggressive variants of papillary thyroid carcinoma. Results: The highest frequency of BRAF V600E among PTC is shown by the high-cell variant of PTC (90%), also significantly higher with «shoe nail» cells than in classical PTC and varies from 40-90%. In a columnar cell, PTC, mutations in the BRAF V600E gene are much less common than in classic PTC. The diffuse sclerosing type of PTC is characterized by the presence of a RET/PTC translocation, and the percentage of the BRAF V600E mutation is 0-60 in various studies. Conclusion: In the presented work, the morphological and clinical features of patients with prognostic unfavorable variants of PTC are considered. Correct recognition of these variants is an important component in the diagnosis of tumor pathology of the thyroid gland, except for accidentally detected microcarcinomas without signs of invasion into the tissues and into the capsule of the thyroid gland and into the lymphatic vessels. The most aggressive forms of PTC include diffuse sclerosing, tall cell, and insular variants of PTC. Various genetic abnormalities, such as BRAF mutation, can be detected in this case. Thus, in some cases these markers can help to predict the course of TC and to provide adequate and timely treatment.
Keywords: thyroid gland, tumor, carcinoma, metastases, histologic types, tall cell features
REFERENCES
1 Giordano D. Frasoldati A. Kasperbauer JL. Gabrielli E. Pernice C. Zini M. Lateral neck recurrence from papillary thyroid carcinoma: predictive factors and
prognostic significance. // Laryngoscope. -2014. https://doi.org/10.1002/lary.25094
2 Pellegriti G. Frasca F. Regalbuto C. Squatrito S. Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors.
– 2013. Article ID 965212.| https://doi.org/10.1155/2013/965212
3 Jung K.K. Little M.P. Lubin J.H. Brenner A.W. Wells S.A. Jr. Sigurdson A.J. Nikiforov E. The rise in thyroid cancer over the past four decades has been
accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J. Clin. Endocr. Metabol. -2014. -Vol. 99.-Р.276–285. https://
doi.org/10.1210/jc.2013-2503
4 Vuong H. Altibi A. Abdelhamid A. Phuong U. Quan V. Mohamed Y. Mohamed E., Tran Le. Ahmed E. Naoki O. Nakazawa T. Kenji H. Ryohei K. Nguyen
T.Tetsuo K. The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review// Oncotarget.- 2017. -Vol. 8(6).
-Р.10637–10649. https://doi.org/10.18632/oncotarget.12885
5 Carrie C Lubitz. Sosa JA. The changing landscape of papillary thyroid cancer: Epidemiology, management, and the implications for patients. // Сancer. –
2016. -Vol.122(24).- Р.3754-3759. https://doi.org/ 10.1002 / cncr.30201
6 Huanli Duan. Yan Li. Peizhen Hu. Jie Gao. Jianming Ying. Wanni Xu. Danhui Zhao. Zhe Wang. Junyi Ye. Analyn Lizaso. Yangzhige He. Huanwen Wu.
Zhiyong Liang. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology.
– 2019. – Vol.75(6).-Р.890-899. https:// doi.org/ 10.1111/his.13942.Epub 2019 Oct 13
7 Ambrosi F. Righi A. Ricci C. Erickson L. Ricardo V. Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review// Endocr Pathol. -2017. Vol. 28(4).-
Р.293-301. https://doi.org/10.1007/s12022-017-9502-7
8 Wang X. Cheng W. Liu C. Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget.
-2016. – Vol. 7 (26). -Р.40792-40799. https://doi.org/10.18632/oncotarget.8215.
9 Zeng C. Long J. Deng C. Xie L. Ma H. Guo Y. Liu S. Deng M. Genetic Alterations in Papillary Thyroid Carcinoma With Hashimoto’s Thyroiditis ANK3, an
Indolent Maintainer of Papillary Thyroid Carcinoma. // Front Oncol.-2022. -Vol.12. https://doi.org/ doi.org/ 10.3389 / fonc.2022.894786
10 Wang X. Cheng W. Liu C. Li J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology //
Oncotarget. – 2016. – Vol. 7(26). – P. 40792-40799. https://doi.org/10.18632/oncotarget.8215
11 Dettmer M.S. Schmitt A. Steinert H. Capper D. Moch H. Komminoth P. Perren A. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations
in BRAF and TERT // Cancers -2019. Vol.11 (6). –Р.885; https://doi.org/10.3390/cancers11060885
12 Oh W.J. Lee Y.S. Cho U. Bae J.S. Lee S. Kim M.H. Lim D.J. Park G.S. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have
similar clinicopathologic features // Korean J.Pathol.-2014. – Vol.48(3).-Р.201-8. https://doi.org/ 10.4132/
13 Vuong HG. Altibi A. Duong U. Hassell L. Vuong HG et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid
carcinoma-A meta-analysis. // Clin Endocr. (Oxf). – 2017. – Vol. 87(5). –Р.411-417 https://doi.org/ 10.1111/cen.13413
14 Bongiovanni M. Mermod M. Canberk Sule. Saglietti C. Gerasimos P et al. Columnar cell variant of papillary thyroid carcinoma: Cytomorphological
characteristics of 11 cases with histological correlation and literature review// Cancer Cytopathol. -2017. – Vol. 125(6). -Р.389-397 https:// doi.org/ 10.1002/
cncy.21860.
15 Ann E Walts. James M Mirocha. Shikha Bose. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and
lymph node status // J Cancer Res Clin Oncol. – 2015.- Vol. 141(10).- Р.1749-56. https:// doi.org/: 10.1007/s00432-015-1939-9
16 Abrosimov AY. Dvinskikh NY. Sidorin AV. Cells of benign and borderline thyroid tumors express malignancy markers. // Bull Exp Biol Med. -2016. – Vol.160(5).
–Р.698-701. https://doi.org/10.1007/s10517-016-32531-1
17 Teng L. Deng W. Lu J. Zhang J. Ren X. Duan H. Chuai S. Duan F. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to
classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma // Oncotarget. -2017.- Vol.28;8(13). –Р.22023-
22033. https://doi.org/ 10.18632/oncotarget.15786
18 Spyroglou A. Kostopoulos G. Tseleni S. Toulis K. Bramis K. Mastorakos G. Konstadoulakis M. Vamvakidis K. Alexandraki K. Hobnail Papillary Thyroid
Carcinoma, A Systematic Review and Meta-Analysis. //Cancers (Basel).- 2022. – Vol.3;14(11). –Р.2785. https:// doi.org/ 10.3390/cancers14112785
19 Vuong H.G. Kondo T. Pham T.Q. Oishi N. Mochizuki K. Nakazawa T. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a
systematic review and metanalyses // Eur J Endocr. – 2017. – Vol. 176(4). –Р.433-441. https:// doi.org/ 10.1530/EJE-16-0863
20 Agrawal N. Akbani R. Aksoy B.A. Ally A., Arachchi H. Asa S.L, Auman J.T. Balasundaram M. Balu S. Baylin S.B. Madhusmita Behera. Brady Bernard.
Rameen Beroukhim. Justin A. Bishop. Aaron D. Black. Tom Bodenheimer. Lori Boice. Moiz S. Bootwalla. Integrated genomic characterization of papillary thyroid
carcinoma // Cell. – 2014. – Vol.159(3). –Р.676-90. https:// doi.org/ 10.1016/j.cell.2014.09.050.
21 Pillai S. Gopalan V. Smith R.A. Lam A.K. Diffuse sclerosing variant of papillary thyroid carcinoma – an update of its clinicopathological features and molecular
biology // Crit. Rev. Oncol/Hematol. -2015. – Vol.94(1). –Р.64-73. https:// doi.org/ 10.1016/j.critrevonc.2014.12.001.
22 Pizzimenti C. Fiorentino V. Ieni A. Martini M. Tuccari G. Lentini M. Fadda G. Aggressive variants of follicular cell-derived thyroid carcinoma: an overview
Endocrine. -2022. – Vol.78(1). –Р.1-12. https:// doi.org/ 10.1007/s12020-022-03146-0
23 Lee CW. Roh JL. Gong G. Cho KJ. Choi SH. Nam SY et al. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral
neck. //Ann Surg Oncol. – 2015. – Vol.22(1). –Р.117–24. https:// doi.org/ 10.1245/s10434-014-3900-6.
